Sepracor's Stedesa gets US FDA complete response letter
This article was originally published in Scrip
The US FDA has hit Sepracor (a US subsidiary of Dainippoin Sumitomo Pharma) with a complete response letter for its new drug application for the once-daily anti-epileptic Stedesa (eslicarbazepine acetate) saying that it will not yet approve it. The drug has been filed as a once-daily adjunctive therapy, in doses of 800mg and 1,200mg, for the maintenance treatment of partial onset seizures in adults.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.